Research Article
Reassessing the Role of the Active TGF-β1 as a Biomarker in Systemic Sclerosis: Association of Serum Levels with Clinical Manifestations
Figure 1
Serum levels of active TGF-1 in healthy controls (HC), systemic sclerosis (SSc) patients, diffuse cutaneous systemic sclerosis (dSSc) patients, and limited cutaneous systemic sclerosis (lSSc) patients. Short horizontal bars represent median. p = 0.001, p < 0.0001, and ns = not significant.